Details

Autor(en) / Beteiligte

• Ellis, Stephen G
• Kereiakes, Dean J
• Metzger, D. Christopher
• Caputo, Ronald P
• Rizik, David G
• Teirstein, Paul S
• Litt, Marc R
• Kini, Annapoorna
• Kabour, Ameer
• Marx, Steven O
• Popma, Jeffrey J
• McGreevy, Robert
• Zhang, Zhen
• Simonton, Charles
• Stone, Gregg W

Titel

Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease

Ist Teil von

• The New England journal of medicine, 2015-11, Vol.373 (20), p.1905-1915

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2015

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• In a randomized trial involving 2008 patients with coronary disease, an everolimus-eluting bioresorbable scaffold was noninferior to an everolimus-eluting cobalt–chromium stent with respect to target-lesion failure at 1 year. Contemporary drug-eluting coronary stents have been associated with better clinical outcomes than have either bare-metal stents or first-generation drug-eluting stents, but ongoing risks of stent thrombosis and restenosis limit their long-term safety and efficacy. 1 – 4 The development of late adverse events with permanent metallic stents may be related to persistent inflammation, loss of normal vessel curvature, impaired vasomotion, strut fracture, ongoing tissue growth within the stent frame, and neoatherosclerosis. 5 , 6 Furthermore, 20 to 30% of patients have recurrent angina during the first year after implantation of a drug-eluting stent. 7 – 9 In this context, stents that are fully bioresorbable have been . . .